Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Long-Term Deferred Tax (2021 - 2023)

Historic Long-Term Deferred Tax for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to $35.4 million.

  • ADC Therapeutics' Long-Term Deferred Tax rose 536.03% to $35.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $35.4 million, marking a year-over-year increase of 536.03%. This contributed to the annual value of $37.1 million for FY2022, which is 14233924.91% up from last year.
  • As of Q3 2023, ADC Therapeutics' Long-Term Deferred Tax stood at $35.4 million, which was up 536.03% from -$8.1 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Long-Term Deferred Tax ranged from a high of $37.1 million in Q4 2022 and a low of -$8.1 million during Q2 2023
  • For the 3-year period, ADC Therapeutics' Long-Term Deferred Tax averaged around $23.7 million, with its median value being $31.8 million (2022).
  • In the last 5 years, ADC Therapeutics' Long-Term Deferred Tax soared by 14233924.91% in 2022 and then plummeted by 12369.27% in 2023.
  • Over the past 3 years, ADC Therapeutics' Long-Term Deferred Tax (Quarter) stood at $26049.0 in 2021, then soared by 142339.25% to $37.1 million in 2022, then fell by 4.59% to $35.4 million in 2023.
  • Its last three reported values are $35.4 million in Q3 2023, -$8.1 million for Q2 2023, and $27.6 million during Q1 2023.